Janssen Stands Ready To Beat Its Peers, Despite Biosimilars
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J expects above industry-average growth through 2019; long-term growth plans were outlined during an analyst day May 20. The strategy depends on new indications for high priority medicines and new launches, with 12 eventual blockbusters to come through 2019.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.